Panelists at American Conference Institute's (ACI) 2020 virtual summit discuss California's legislative attempts to improve competition in the drug industry.
Recent attempts at reform across the biosimilar and generic drug landscape have not had unanimous support, legal experts noted at the American Conference Institute’s 11th Summit on Biosimilars & Innovator Biologics.
Last year, for example, California, enacted Assembly Bill (AB) 824, which enabled it to evaluate “pay for delay” settlements between biosimilar developers and reference product companies and bring enforcement actions for what it perceives as anticompetitive terms.
“That legislation is doing what the Supreme Court declined to do, which is impose a presumption that an agreement that includes certain terms has an anticompetitive effect,” said ACI panelist Karin Hessler, assistant general counsel for the Association for Accessible Medicines (AAM). The AAM has filed a series of court actions designed to overturn AB 824, but has thus far been unsuccessful.
The AAM represents many large biosimilar developers and contends that California has improperly assumed the right to reject corporate settlements reached outside the state and also given itself leeway to impose excessive fines on individual companies (minimum of $20 million).
Another reason the pharmaceutical industry opposes this law is that it gives California the ability to review and evaluate all individual past settlements between drug companies, not just new settlements, said panelist David Korn, vice president of Intellectual Property and Law with the Pharmaceutical Research and Manufacturers of America.
If other states join in with regulations of their own, the operational environment for pharmaceutical companies could become far too restrictive, he said. “This should be left up to Congress, because if you have multiple state-based frameworks, it could create a patchwork [of laws] that would be harder to comply with.”
Hessler said there’s potential that patent settlements between companies will be “stifled” by this legislation. “If you have that sort of impact, then you may see generic and biosimilar companies not as frequently challenging patents, which ultimately could result in higher rather than lower drug prices,” she said.
In addition, California Governor Gavin Newsom has until the end of this month to sign or veto AB 852, a bill that would enable the state to contract for the manufacture of generic and biosimilar drugs. One of the driving thoughts behind this bill is that “there has to be a more viable pathway for producing an affordable insulin,” Hessler said.
The legal and pharmaceutical industries are watching this bill closely, the panel said.
“There are certainly provisions in the bill that talk about sales to California payers, but I think the assumption is that (drugs) would be distributed potentially nationally,” Hessler said.
Reference
Brand M, Korn D, Hessler K, Pearson M. Biosimilars state of the union: regulatory and legislative developments impacting the biopharmaceutical industry. Presented at: ACI 11th Summit on Biosimilars & Innovator Biologics; September 23, 2020.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.